FDA Clears QIAGEN's Gram-Negative Panel, Completing U.S. Bloodstream Infection Portfolio
QGEN sits 36% above its 52-week low of $32.53.
Summary
QIAGEN received FDA clearance for its QIAstat-Dx BCID GN Plus AMR Panel, which detects 13 gram-negative bacterial pathogens and 18 antimicrobial resistance markers in about one hour. This completes the U.S. bloodstream infection portfolio, complementing the gram-positive and fungal panel cleared in August. Together the two panels cover 33 pathogen targets and 28 resistance markers on the same automated system. The clearance expands QIAGEN's infectious disease menu in the U.S. and strengthens its competitive position in rapid syndromic testing, a market with significant clinical demand given sepsis's high mortality. The company has over 5,200 cumulative QIAstat-Dx placements globally, providing an installed base for adoption. This follows the August 10 FDA clearance of the gram-positive panel and comes amid ongoing private equity takeover interest from EQT, Advent, KKR, TPG, and Bain.
At the time of this announcement, QGEN was trading at $44.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $32.53 to $57.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.